ADAMA Ltd. is introducing a novel proprietary formulation technology, resulting in higher efficacy in ADAMA’s prothioconazole-based products.
ADAMA’s novel fungicide formulation based on the company’s own Asorbital Formulation Technology combines its unique mix of solvents and surfactants, creating a new and extraordinary carrier technology that increases efficacy to improve crop yield while reducing environmental impact. The new formulation with the built-in adjuvant moves the fungicide beyond the generic active ingredient by increasing its penetration efficiency and providing excellent systemic movement through the plant to speed up delivery from the point of contact on the leaf to the site of action within the fungal cell.
In the UK, ADAMA continued its global roll-out of one of its self-produced prothioconazole-based products, SORATEL. This is ADAMA’s first product featuring the new Asorbital Formulation Technology and offers improved cereal and OSR disease control compared to competitor products. Based on field trials conducted in the UK, SORATEL is up to 13% more effective against fusarium and up to 8% more effective against Septoria than the current market leader.
“This new Asorbital Formulation Technology is part of ADAMA’s commitment to listen to farmers in the field and deliver innovative products that improve crop yield while raising the bar for sustainability,” said Walter Costa, VP of vice president of marketing and product strategy.
SORATEL, ADAMA’s first prothioconazole-based products featuring the new Asorbital Formulation Technology is launching in the UK, Australia, Canada, as well as New Zealand, and the company is continuing to progress towards obtaining registrations for this product in other global markets. More prothioconazole-based products featuring the Asorbital formulation technology will be launched in the future.
The company launched its first self-produced prothioconazole-based product ARMERO, a dual-mode fungicide containing the active ingredients prothioconazole and mancozeb, benefiting from its in-house production of prothioconazole, in Paraguay in December 2019.
